OTLK supply chain intelligence for Outlook Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| H-C-WAINWRIGHT-CO-LLC | H-C-WAINWRIGHT-CO-LLC | 90% | The Company will pay H.C. Wainwright a commission equal to 3% of the aggregate gross proceeds of any sale of Shares under the Sales Agreement. |
| SELEXIS-SA | SELEXIS-SA | 85% | We have in-licensed certain technology from Selexis SA, or Selexis, that we used to research and develop our product candidates. |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: on, patient education, reimbursement and market access, trade and distribution, commercial operations, commercial analytics, and market research. In addition,… |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: Reciprocal relationship from OTLK graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CENCORA | CENCORA | 90% | If we are unable to establish sales and marketing capabilities for any approved product, whether on our own or through collaborations, including through the strategic collaboration agreement with Cen… |
| SYNTONE-VENTURES-LLC | SYNTONE-VENTURES-LLC | 80% | In May 2020, we entered into a stock purchase agreement with Syntone Ventures LLC, or Syntone, pursuant to which we sold and issued, in a private placement in June 2020, 800,000 shares of our common … |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that … |
| BEIJING-SYNTONE-BIOPHARMA-LTD | BEIJING-SYNTONE-BIOPHARMA-LTD | 62% | L in August 2023. Loss on Equity Method Investment Loss on equity method investment represents our share of the loss from Beijing Syntone Biopharma Ltd, or Syntone JV. Interest Income Interest income… |
| COORDINATION-GROUP | COORDINATION-GROUP | 62% | e abbreviated approval pathway that are still being worked out by the FDA. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date… |
| ESSEX-BIO-TECHNOLOGY-LTD | ESSEX-BIO-TECHNOLOGY-LTD | 62% | ecuted a supply agreement for a best-in-class pre-filled ophthalmic syringe, which we believe will provide both ease-of-use for clinicians and add to ONS-5010/LYTENAVA’s safety profile over the curre… |
| SHANGHAI-HENLIUS-BIOTECH-INC | SHANGHAI-HENLIUS-BIOTECH-INC | 62% | ecuted a supply agreement for a best-in-class pre-filled ophthalmic syringe, which we believe will provide both ease-of-use for clinicians and add to ONS-5010/LYTENAVA’s safety profile over the curre… |
| STADA-ARZNEIMITTEL-AG | STADA-ARZNEIMITTEL-AG | 62% | ecuted a supply agreement for a best-in-class pre-filled ophthalmic syringe, which we believe will provide both ease-of-use for clinicians and add to ONS-5010/LYTENAVA’s safety profile over the curre… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| OTLK-DEBT | Debt stack $36.9M | 90% | Market cache reports total debt of $36.9M. |
| OTLK-DEBT-11619 | Warrants outstanding: 56828913 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| OTLK-DEBT-11620 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-09-30. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| OTLK-OWNER-WARBERG-ASSET-MANAGEMENT-LLC | Warberg Asset Management LLC | 95% | 13F/ownership overlay lists Warberg Asset Management LLC; shares held 275,000; ownership 0.26%; value $63,579; as of 2026-03-31. |
| OTLK-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 316,464; ownership 0.30%; value $73,166; as of 2025-12-31. |
| OTLK-OWNER-SCHONFELD-STRATEGIC-ADVISORS-LLC | Schonfeld Strategic Advisors Llc | 95% | 13F/ownership overlay lists Schonfeld Strategic Advisors Llc; shares held 2,441,355; ownership 2.33%; value $564,441; as of 2025-12-31. |
| OTLK-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | Vanguard Capital Management LLC | 95% | 13F/ownership overlay lists Vanguard Capital Management LLC; shares held 1,967,160; ownership 1.88%; value $454,807; as of 2026-03-31. |
| OTLK-OWNER-GILPIN-WEALTH-MANAGEMENT-LLC | Gilpin Wealth Management, LLC | 95% | 13F/ownership overlay lists Gilpin Wealth Management, LLC; shares held 600,162; ownership 0.57%; value $138,757; as of 2026-03-31. |
| OTLK-OWNER-COMMONWEALTH-EQUITY-SERVICES-LLC | Commonwealth Equity Services, LLC | 95% | 13F/ownership overlay lists Commonwealth Equity Services, LLC; shares held 470,000; ownership 0.45%; value $108,663; as of 2026-03-31. |
| OTLK-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 404,542; ownership 0.39%; value $93,530; as of 2025-12-31. |
| OTLK-OWNER-MARSHALL-WACE-LLP | Marshall Wace LLP | 95% | 13F/ownership overlay lists Marshall Wace LLP; shares held 298,456; ownership 0.29%; value $69,003; as of 2025-12-31. |
| OTLK-OWNER-SUSQUEHANNA-INTERNATIONAL-GROUP-LLP | Susquehanna International Group, LLP | 95% | 13F/ownership overlay lists Susquehanna International Group, LLP; shares held 172,022; ownership 0.16%; value $39,771; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics, Inc. | 100.00 | 2 | |
| RGNX | REGENXBIO Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | ['supplier'] |
| LLY | Eli Lilly and Company | 100.00 | 2 | |
| NVSEF | Novartis AG | 100.00 | 2 | |
| OCUL | Ocular Therapeutix, Inc. | 100.00 | 2 | |
| UCSD | UCSD | 50.00 | 2 | |
| TSHA | Taysha Gene Therapies, Inc. | 50.00 | 2 | |
| DNLI | Denali Therapeutics Inc. | 50.00 | 2 | |
| TNYA | Tenaya Therapeutics, Inc. | 50.00 | 2 | |
| SRPT | Sarepta Therapeutics, Inc. | 50.00 | 2 | |
| RARE | Ultragenyx Pharmaceutical Inc. | 50.00 | 2 | |
| KLRS | Kalaris Therapeutics, Inc. | 36.29 | 1 | ['spend'] |